P3-RISIL ECO

Glavne informacije

  • Zaščiteno ime:
  • P3-RISIL ECO
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • P3-RISIL ECO
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 113703E
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

1 / 14

ODDELEK 1: Identifikacija snovi/zmesi in družbe/podjetja

1.1 Identifikator izdelka

Ime proizvoda

P3-risil ECO

Koda proizvoda

113703E

Uporaba snovi/zmesi

Čistilo

Vrsta snovi

Zmes

Samo za poklicne uporabnike.

Podatki o redčenju izdelka

Podatkov o redčenju ni na voljo.

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Identifikacija uporabe

Procesno čiščenje; Cleaning In place (CIP) postopek

Priporočene omejitve

uporabe

Samo za industrijsko in profesionalno uporabo.

1.3 Podrobnosti o dobavitelju varnostnega lista

Družba

Ecolab d.o.o.

Vajngerlova ulica 4

2000, Maribor Slovenija 02 429 3100 (Delavnik: 8:00 - 16:00)

narocila@ecolab.com

1.4 Telefonska številka za nujne primere

Telefonska številka za nujne

primere

+38682880010

+32-(0)3-575-5555 Transevropski

Telefonska številka Centra

za zastrupitve

Datum sestavitve/Revizije

18.07.2017

Verzija

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Razvrstitev (UREDBA (ES) št. 1272/2008)

Jedkost za kožo, Kategorija 1.A

H314

Huda poškodba oči, Kategorija 1

H318

2.2 Elementi etikete

Etiketiranje (UREDBA (ES) št. 1272/2008)

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

2 / 14

Piktogrami za nevarnost

Opozorilna beseda

Nevarno

Opozorila o nevarnosti

H314

Povzroča hude opekline kože in poškodbe oči.

Obvestila o nevarnosti

Preprečevanje:

P280

Nositi zaščitne rokavice/ zaščito za oči/ zaščito

za obraz.

Odziv:

P303 + P361 + P353

PRI STIKU S KOŽO (ali lasmi): Takoj sleči

vsa kontaminirana oblačila. Izprati kožo z

vodo/prho.

P305 + P351 + P338

PRI STIKU Z OČMI: previdno izpirajte z

vodo nekaj minut. Odstranite kontaktne leče,

če jih imate in če to lahko storite brez težav.

Nadaljujte z izpiranjem.

P310

Takoj pokličite CENTER ZA

ZASTRUPITVE/zdravnika.

Nevarne komponente, ki morajo biti naštete na nalepki/etiketi:

natrijev hidroksid

2.3 Druge nevarnosti

Nobena znana.

ODDELEK 3: Sestava/podatki o sestavinah

3.2 Zmesi

Nevarne sestavine

Kemijsko ime

Št. CAS

ES-št.

Št. REACH

RazvrstitevUREDBA (ES) št. 1272/2008

Koncentracija:

natrijev hidroksid

1310-73-2

215-185-5

01-2119457892-27

Jedkost za kožo Kategorija 1.A; H314

Jedko za kovine Kategorija 1; H290

>= 10 - < 20

amidi, koko, N-[3-

(dimetilamino)propil],

produkti alkilacije s

kloroocetno kislino,

natrijeve soli

70851-07-9

274-923-4

Huda poškodba oči Kategorija 1; H318

>= 3 - < 4

Etoksilati maščobnega

alkohola =/< C15 in =/<

68213-23-0

500-201-8

Akutna strupenost Kategorija 4; H302

Draženje oči Kategorija 2; H319

>= 1 - < 2.5

C8-10 poliglikozid

68515-73-1

500-220-1

01-2119488530-36

Huda poškodba oči Kategorija 1; H318

>= 1 - < 2.5

Za celotno besedilo H-stavkov, omenjenih v tem Oddelku, glej Oddelek 16.

ODDELEK 4: Ukrepi za prvo pomoč

4.1 Opis ukrepov za prvo pomoč

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

3 / 14

Pri stiku z očmi

Takoj začeti izpirati z obilo vode, tudi pod vekami, najmanj 15

minut. Odstranite kontaktne leče, če jih imate in če to lahko storite

brez težav. Nadaljujte z izpiranjem. Takoj pokličite zdravnika.

Pri stiku s kožo

Takoj umivajte/izpirajte z obilo vode vsaj 15 minut. Po možnosti

uporabljati blago milo. Operite kontaminirana oblačila pred

ponovno uporabo. Pred uporabo temeljito očistiti obutev. Takoj

pokličite zdravnika.

Pri zaužitju

Izprati usta z vodo. NE izzivati bruhanja. Nikoli ne dajajte ničesar v

usta nezavestni osebi. Takoj pokličite zdravnika.

Pri vdihavanju

Premestiti na svež zrak. Simptomatsko zdravljenje. Če se pojavijo

simptomi, poiskati zdravniško pomoč.

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptome.

4.3 Navedba kakršne koli takojšnje medicinske oskrbe in posebnega zdravljenja

Zdravljenje

Simptomatsko zdravljenje.

ODDELEK 5: Protipožarni ukrepi

5.1 Sredstva za gašenje

Ustrezna sredstva za

gašenje:

Uporabljajte gasilne ukrepe, ki so primerni lokalnim okoliščinam in

bližnjemu okolju.

Neustrezna sredstva za

gašenje

Nobena znana.

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

Specifične nevarnosti med

gašenjem

Ni vnetljivo ali gorljivo.

Nevarni proizvodi izgorevanja

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforjevi oksidi

5.3 Nasvet za gasilce

Posebna zaščitna oprema za

gasilce

: Uporabljajte osebno varovalno opremo.

Dodatne informacije

: Ostanke po požaru in kontaminirano vodo za gašenje požara je

treba varno odstraniti v skladu z lokalnimi predpisi. Pri požaru

in/ali eksploziji ne vdihavajte dima.

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

4 / 14

Nasvet za neizučeno osebje

Zagotovite zadostno prezračevanje. Preprečite ljudem dostop do

izpusta/razliva in v protivetrni smeri od izpusta/razliva. Izogibati se

vdihavanju, zaužitju ter stiku s kožo in očmi. Če so delavci

izpostavljeni koncentracijam nad dovoljenimi mejnimi vrednostmi,

morajo uporabljati ustrezno obrazno masko. Zagotovite, da

čiščenje izvaja samo usposobljeno osebje. Glej zaščitne ukrepe,

navedene v Oddelkih 7 in 8.

Nasvet za reševalce

Če so pri rokovanju z razlitjem zahtevana specialna oblačila,

upoštevati podatke o primernih in neprimernih materialih v

Oddelku 8.

6.2 Okoljevarstveni ukrepi

Okoljevarstveni ukrepi

Preprečiti, da pride v stik z zemljo, površinsko vodo ali podtalnico.

6.3 Metode in materiali za zadrževanje in čiščenje

Metode čiščenja

Zaustaviti puščanje, če je varno. Zajeziti in zadržati izlitje z

negorljivim absorpcijskim materialom (npr. peskom, zemljo,

diatomejsko zemljo, vermikulitom) in prenesti v vsebnik za

odstranjevanje skladno z lokalnimi/nacionalnimi predpisi (glej

Oddelek 13).Splakniti sledi z vodo. Pri večjih razlitjih zajeziti ali

drugače zadržati razlito snov in s tem zagotoviti, da ne doseže

vodotokov.

6.4 Sklicevanje na druge oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Glej Oddelek 8 za podatke o osebni zaščiti.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

ODDELEK 7: Ravnanje in skladiščenje

7.1 Varnostni ukrepi za varno ravnanje

Navodilo za varno rokovanje

Ne zaužiti. Preprečiti stik z očmi, kožo ali oblačili. Ne vdihavati

prahu/dima/plina/meglice/hlapov/razpršila. Uporabljati samo ob

ustreznem prezračevanju. Po uporabi temeljito umiti roke.

Higienski ukrepi

Ravnajte v skladu z dobro proizvodno in varnostno prakso.

Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

7.2 Pogoji za varno skladiščenje, vključno z nezdružljivostjo

Zahteve glede skladiščnih

prostorov in vsebnikov

Ne skladiščiti v bližini kislin. Hraniti zunaj dosega otrok. Hraniti v

tesno zaprti posodi. Hraniti v posodah z ustreznimi nalepkami.

Temperatura pri skladiščenju

-10 °C do 40 °C

7.3 Posebne končne uporabe

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

5 / 14

Posebni način(-i) uporabe

Procesno čiščenje; Cleaning In place (CIP) postopek

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Mejne vrednosti za poklicno izpostavljenost

Sestavine

Št. CAS

Tip vrednosti

(Oblika

izpostavljanja)

Parametri nadzora

Osnova

natrijev hidroksid

1310-73-2

MV (Inhalabilna

frakcija)

2 mg/m3

SI OEL

Dodatne informacije

Inhalabilna frakcija - del celotne suspendirane snovi, ki jo delavec vdihne

Snovi, pri katerih ni nevarnosti za zarodek ob upoštevanju mejnih vrednosti in

BAT vrednosti.

DNEL

Natrijev hidroksid

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni lokalni učinki

Vrednost: 1 mg/m3

Končna uporaba: Potrošniki

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni lokalni učinki

Vrednost: 1 mg/m3

Etoksilati maščobnega

alkohola =/< C15 in =/< 5EO

Končna uporaba: Delavci

Načini izpostavljenosti: Kožno

Potencialni učinki na zdravje: Dolgoročni sistemski učinki

Končna uporaba: Delavci

Načini izpostavljenosti: Vdihavanje

Potencialni učinki na zdravje: Dolgoročni sistemski učinki

Vrednost: 294 mg/m3

PNEC

Etoksilati maščobnega

alkohola =/< C15 in =/< 5EO

Sladka voda

Vrednost: 0.048 mg/l

Morska voda

Vrednost: 0.048 mg/l

Prekinjena uporaba/izpust

Vrednost: 0.0041 mg/l

Naprava za čiščenje odplak

Vrednost: 10000 mg/l

Usedlina v sladki vodi

Vrednost: 292 mg/kg

Usedlina v morju

Vrednost: 292 mg/kg

Vrednost: 1 mg/kg

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

6 / 14

8.2 Nadzor izpostavljenosti

Ustrezni inženirski mehanizmi

Tehnični ukrepi

Učinkovit izpušni prezračevalni sistem. Ohranjati vrednosti

koncentracij v zraku znotraj standardov za poklicno

izpostavljenost.

Individualni zaščitni ukrepi

Higienski ukrepi

Ravnajte v skladu z dobro proizvodno in varnostno prakso.

Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

Zaščita za oči / obraz (EN

166)

Varovalna očala

Obrazni ščitnik

Zaščita rok (EN 374)

Priporočena preventivna zaščita kože

Rokavice

Nitrilni kavčuk

butilni kavčuk

Prebojni čas: 1 - 4 ure

Minimalna debelina rokavic iz butilne gume je 0.7mm, iz nitrilne

gume 0.4mm oz. enakovredno (upoštevati navodila

proizvajalca/distributerja rokavic).

Če se pojavijo kakršni koli znaki razkroja rokavic ali prodora

kemikalij skozi rokavice, je treba le-te odstraniti in jih zamenjati z

novimi.

Zaščita kože (EN 14605)

Osebna zaščitna oprema, vsebujoč: prilegajoče se zaščitne

rokavice, zaščitna očala in zaščitno obleko

Zaščita dihal (EN 143,

14387)

Ni potrebna, če se koncentracija nevarnih snovi v zraku ohrani

pod mejnimi vrednostmi, navedenimi v podatkih o mejnih

vrednostih izpostavitve. Uporabiti certificirano dihalno napravo,

skladno z zahtevami Direktiv 89/656/EGS in 89/686/EGS ali

enakovredno, kadar se tveganju za dihala ni mogoče izogniti s

tehničnimi varovalnimi sredstvi in ukrepi, metodami ali postopki

organizacije dela.

Nadzor izpostavljenosti okolja

Splošna navodila

: Razmislite o ukrepih glede zadrževanja okoli posod za

skladiščenje.

ODDELEK 9: Fizikalne in kemijske lastnosti

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Videz

: tekočina

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

7 / 14

Barva

: svetlo rumena

Vonj

: brez vonja

13.9 - 14.1, 100 %

Plamenišče

Se ne upošteva.

Mejne vrednosti vonja

Ni primerno in/ali ni določeno za zmesi

Tališče/ledišče

Ni primerno in/ali ni določeno za zmesi

Začetno vrelišče in območje

vrelišča

100 °C

Hitrost izparevanja

Ni primerno in/ali ni določeno za zmesi

Vnetljivost (trdno, plinasto)

Ni primerno in/ali ni določeno za zmesi

Zgornja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Spodnja meja eksplozivnosti

Ni primerno in/ali ni določeno za zmesi

Parni tlak

Ni primerno in/ali ni določeno za zmesi

Relativna gostota par/hlapov

Ni primerno in/ali ni določeno za zmesi

Relativna gostota

1.13 - 1.17

Topnost v vodi

topno

Topnost v drugih topilih

Ni primerno in/ali ni določeno za zmesi

Porazdelitveni koeficient: n-

oktanol/voda

Ni primerno in/ali ni določeno za zmesi

Temperatura samovžiga

Ni primerno in/ali ni določeno za zmesi

Toplotni razpad/razgradnja

Ni primerno in/ali ni določeno za zmesi

Viskoznost, kinematična

Ni primerno in/ali ni določeno za zmesi

Eksplozivne lastnosti

Ni primerno in/ali ni določeno za zmesi

Oksidativne lastnosti

Snov ali zmes ni razvrščena kot oksidativna.

9.2 Drugi podatki

Ni primerno in/ali ni določeno za zmesi

ODDELEK 10: Obstojnost in reaktivnost

10.1 Reaktivnost

Nevarne reakcije pri normalni uporabi niso znane.

10.2 Kemijska stabilnost

Stabilno pri normalnih pogojih.

10.3 Možnost poteka nevarnih reakcij

Nevarne reakcije pri normalni uporabi niso znane.

10.4 Pogoji, ki se jim je treba izogniti

Nobena znana.

10.5 Nezdružljivi materiali

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

8 / 14

Kisline

Kovine

10.6 Nevarni produkti razgradnje

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforjevi oksidi

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Podatki o možnih načinih

izpostavljenosti

Vdihavanje, Stik z očmi, Stik s kožo

Proizvod

Akutna oralna strupenost

: Ocena akutne strupenosti : > 2,000 mg/kg

Akutna toksičnost pri

vdihavanju

: Za ta proizvod ni na voljo podatkov.

Akutna dermalna strupenost

: Za ta proizvod ni na voljo podatkov.

Jedkost za kožo/draženje

kože

: Za ta proizvod ni na voljo podatkov.

Resne okvare oči/draženje

: Za ta proizvod ni na voljo podatkov.

Preobčutljivost pri vdihavanju

in preobčutljivost kože

: Za ta proizvod ni na voljo podatkov.

Rakotvornost

: Za ta proizvod ni na voljo podatkov.

Učinki na razplojevanje

: Za ta proizvod ni na voljo podatkov.

Mutagenost za zarodne

celice

: Za ta proizvod ni na voljo podatkov.

Teratogenost

: Za ta proizvod ni na voljo podatkov.

STOT - enkratna

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

STOT - ponavljajoča se

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

Toksičnost pri vdihavanju

: Za ta proizvod ni na voljo podatkov.

Sestavine

Akutna oralna strupenost

: amidi, koko, N-[3-(dimetilamino)propil], produkti alkilacije s

kloroocetno kislino, natrijeve soli

LD50 Podgana: 2,600 mg/kg

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

9 / 14

Etoksilati maščobnega alkohola =/< C15 in =/< 5EO

LD50 Podgana: 1,700 mg/kg

C8-10 poliglikozid

LD50 Podgana: > 5,000 mg/kg

Sestavine

Akutna dermalna strupenost

: Etoksilati maščobnega alkohola =/< C15 in =/< 5EO

LD50 Kunec: > 2,000 mg/kg

C8-10 poliglikozid

LD50 Kunec: > 2,000 mg/kg

Možni učinki na zdravje

Oči

Povzroča hude poškodbe oči

Koža

Povzroča hude opekline kože.

Zaužitje

Povzroča opekline prebavnega trakta.

Vdihavanje

Lahko povzroči draženje nosu, grla in pljuč.

Kronična izpostavljenost

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Izkušnje z izpostavljenostjo človeka

Stik z očmi

Rdečina, Bolečina, Razjede

Stik s kožo

Rdečina, Bolečina, Razjede

Zaužitje

Razjede, bolečina v trebuhu

Vdihavanje

Razdraženost dihal, Kašelj

ODDELEK 12: Ekološki podatki

12.1 Ekotoksičnost

Učinki na okolje

Ta proizvod nima znanih strupenih učinkov na okolje.

Proizvod

Strupenost za ribe

: Ni razpoložljivih podatkov

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Ni razpoložljivih podatkov

Strupenost za alge

: Ni razpoložljivih podatkov

Sestavine

Strupenost za ribe

: amidi, koko, N-[3-(dimetilamino)propil], produkti alkilacije s

kloroocetno kislino, natrijeve soli

96 h LC50 Ribe: 2 mg/l

Etoksilati maščobnega alkohola =/< C15 in =/< 5EO

96 h LC50 Ribe: 1.5 mg/l

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

10 / 14

Sestavine

Strupenost za vodno bolho in

druge vodne vretenčarje.

: natrijev hidroksid

48 h EC50: 40 mg/l

Sestavine

Strupenost za alge

: C8-10 poliglikozid

72 h EC50: 18 mg/l

12.2 Obstojnost in razgradljivost

Proizvod

Biorazgradljivost

: V proizvodu vsebovane površinsko aktivne snovi so

biorazgradljive v skladu z Uredbo o detergentih 648/2004/EC.

Sestavine

Biorazgradljivost

natrijev hidroksid

Rezultat: Se ne upošteva - anorgansko

amidi, koko, N-[3-(dimetilamino)propil], produkti alkilacije s

kloroocetno kislino, natrijeve soli

Rezultat: Zlahka biorazgradljivo.

Etoksilati maščobnega alkohola =/< C15 in =/< 5EO

Rezultat: Zlahka biorazgradljivo.

C8-10 poliglikozid

Rezultat: Zlahka biorazgradljivo.

12.3 Zmožnost kopičenja v organizmih

Ni razpoložljivih podatkov

12.4 Mobilnost v tleh

Ni razpoložljivih podatkov

12.5 Rezultati ocene PBT in vPvB

Proizvod

Ocena

Snov/zmes ne vsebuje komponent, ki so obstojne,

bioakumulacijske in strupene (PBT) ali izredno obstojne in zelo

bioakumulacijske (vPvB) v koncentracijah 0,1% ali več.

12.6 Drugi škodljivi učinki

Ni razpoložljivih podatkov

ODDELEK 13: Odstranjevanje

Odložiti v skladu z evropskimi direktivami o odpadkih in nevarnih odpadkih.Odpadkom naj bi kode

pripisal uporabnik, prednostno po posvetu z organi, ki so pristojni za odstranjevanje odpadkov.

13.1 Metode ravnanja z odpadki

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

11 / 14

Proizvod

: Kjer je mogoče, ima recikliranje prednost pred odlaganjem ali

sežiganjem. Če recikliranje ni izvedljivo, odstraniti skladno z

lokalnimi predpisi. Odpad odlagajte v odobrenih objektih za

odlaganje odpada.

Kontaminirana

embalaža/pakiranje

: Odstranite kot nerabljen proizvod. Prazne posode je treba

dostaviti pooblaščeni osebi za ravnanje z odpadki na recikliranje

ali odlaganje. Prazni vsebniki niso za ponovno uporabo. Odstraniti

skladno z lokalnimi, državnimi in zveznimi predpisi.

Napotki za izbiro kode

odpadka

: Anorganski odpadki, ki vsebujejo nevarne snovi. Če se ta proizvod

uporablja v katerih koli nadaljnjih postopkih, mora končni

uporabnik opredeliti in določiti najprimernejšo kodo odpadka glede

na Evropski seznam odpadkov. Odgovornost povzročitelja

odpadkov je, da določi strupenost in fizikalne lastnosti nastalega

materiala ter določi ustrezne metode identifikacije in

odstranjevanje odpadkov, skladno z veljavnimi evropskimi (EU

Direktiva 2008/98/ES) in lokalnimi predpisi.

ODDELEK 14: Podatki o prevozu

Špediter/pošiljatelj/dobavitelj je odgovoren zagotoviti, da so embalaža, oznake in nalepke za

označevanje nevarnosti skladni z izbranim načinom prevoza.

Transport po kopnem (ADR/ADN/RID)

14.1 Številka ZN

1824

14.2 Uradno ime blaga ZN

RAZTOPINA NATRIJEVEGA HIDROKSIDA

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

Noben

Zračni transport (IATA)

14.1 Številka ZN

1824

14.2 Uradno ime blaga ZN

Sodium hydroxide solution

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

None

Pomorski transport

(IMDG/IMO)

14.1 Številka ZN

1824

14.2 Uradno ime blaga ZN

SODIUM HYDROXIDE SOLUTION

14.3 Razredi nevarnosti

prevoza

14.4 Embalažna skupina

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

None

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II k

MARPOL 73/78 in Kodeksom

Not applicable.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

12 / 14

IBC

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

v skladu z Uredbo o

detergentih ES 648/2004

manj kot 5 %: Neionske površinsko aktivne snovi

Nacionalni predpis

Upoštevajte direktivo 94/33/ES o varstvo mladih ljudi pri delu.

Razred skladiščenja

Drugi predpisi

Zakon o kemikalijah

Pravilnik o tehničnih in organizacijskih ukrepih za skladiščenje

nevarnih kemikalij

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu (Uradni list RS, št.

100/01, 39/05, 53/07, 102/10, 43/11 -- ZVZD-1, 38/15)

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti rakotvornim ali mutagenim snovem

Pravilnik o osebni varovalni opremi, ki jo delavci uporabljajo pri

delu

Pravilnik o varovanju zdravja pri delu otrok, mladostnikov in

mladih oseb

Pravilnik o varovanju zdravja pri delu nosečih delavk, delavk, ki so

pred kratkim rodile ter doječih delavk

Zakon o varstvu okolja

Uredba o odpadkih

Uredba o ravnanju z embalažo in odpadno embalažo

Zakon o prevozu nevarnega blaga

15.2 Ocena kemijske varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

ODDELEK 16: Drugi podatki

Način, na katerega je bila določena razvrstitev

UREDBA (ES) št. 1272/2008

Razvrstitev

Utemeljitev

Jedkost za kožo 1.A, H314

Metoda izračuna

Huda poškodba oči 1, H318

Metoda izračuna

Celotno besedilo H-stavkov

H290

Lahko je jedko za kovine.

H302

Zdravju škodljivo pri zaužitju.

H314

Povzroča hude opekline kože in poškodbe oči.

H318

Povzroča hude poškodbe oči

H319

Povzroča hudo draženje oči.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

13 / 14

Celotno besedilo drugih okrajšav

ADN - Evropski sporazum o mednarodnem prevozu nevarnih snovi po celinskih vodah; ADR -

Evropski sporazum o mednarodnem prevozu nevarnih snovi po cesti; AICS - Avstralski popis

kemičnih snovi; ASTM - Ameriško združenje za testiranje materialov; bw - Telesna teža; CLP -

Uredba o razvrščanju, označevanju in pakiranju; Uredba (ES) št. 1272/2008; CMR - Karcinogena,

mutagena strupena snov ali snov, strupena za razmnoževanje; DIN

- Standard nemškega

inštituta za standardizacijo; DSL - Seznam domačih snovi (Kanada); ECHA - Evropska agencija

za kemikalije; EC-Number - Evropska številka Skupnosti; ECx - Koncentracija, povezana z x%

odzivom; ELx - Stopnja obremenitve, povezana z x% odzivom; EmS - Načrt v sili; ENCS -

Obstoječe in nove kemične snovi (Japonska); ErCx - Koncentracija, povezana z x% odzivom

stopnje rasti; GHS - Globalno usklajeni sistem; GLP - Dobra laboratorijska praksa; IARC -

Mednarodna agencija za raziskave raka; IATA - Mednarodno združenje letalskih prevoznikov;

IBC - Mednarodni kodeks za gradnjo in opremo ladij, ki prevažajo nevarne kemikalije v razsutem

stanju; IC50 - Polovična največja inhibitorna koncentracija; ICAO - Mednarodna organizacija

civilnega letalstva; IECSC - Kitajski seznam obstoječih kemičnih snovi; IMDG - Mednarodni

kodeks za prevoz nevarnih snovi po morju; IMO - Mednarodna pomorska organizacija; ISHL -

Zakon

varnosti

zdravju

delu

(Japonska);

Mednarodna

organizacija

standardizacijo; KECI - Korejski seznam obstoječih kemikalij; LC50 - Smrtna koncentracija za

50% testirane populacije; LD50 - Smrtni odmerek za 50% testirane populacije (srednji smrtni

odmerek); MARPOL - Mednarodna konvencija o preprečevanju onesnaževanja morja z ladij;

n.o.s. - Nikjer drugje navedeno; NO(A)EC - Koncentracija brez opaznega (škodljivega) učinka;

NO(A)EL - Raven brez opaznega (škodljivega) učinka; NOELR - Stopnja obremenitve brez

opaznega učinka; NZIoC - Novozelandski popis kemikalij; OECD - Organizacija za gospodarsko

sodelovanje in razvoj; OPPTS - Urad za kemijsko varnost in preprečevanje onesnaževanja; PBT -

Snov, ki je obstojna, se kopiči v organizmih in je strupena; PICCS - Filipinski seznam kemikalij in

kemičnih snovi; (Q)SAR - (Kvantitativno) razmerje med strukturo in aktivnostjo; REACH - Uredba

(ES) št. 1907/2006 Evropskega parlamenta in Sveta o registriranju, vrednotenju, potrjevanju in

omejevanju kemikalij; RID - Pravilniki o mednarodnem železniškem prevozu nevarnega blaga;

SADT - Samopospešujoča temperatura razgradnje; SDS - Varnostni list; TCSI - Tajvanski popis

kemičnih snovi; TRGS - Tehnično pravilo za nevarne snovi; TSCA - Zakon o nadzoru strupenih

snovi (ZDA); UN - Združeni narodi; vPvB - Zelo obstojno in se zelo lahko kopiči v organizmih

Pripravil

Regulatory Affairs

Številke, navedene v varnostnem listu, so podane v obliki: 1,000,000=1 milijon in 1,000=1 tisoč.

0.1 = 1 desetina in 0.001 = 1 tisočina.

SPREMEMBE PODATKOV: Pomembne spremembe podatkov o predpisih in zdravju pri tej

popravljeni izdaji so nakazane s črto ob levem robu varnostnega lista.

Informacija v tem Varnostnem listu je pravilna po našem najboljšem znanju, informacijah in

prepričanju na dan njegove objave. Informacija je zasnovana samo kot napotilo za varno

rokovanje, uporabo, obdelavo/predelavo, shranjevanje/skladiščenje, transport, odstranjevanje in

izpust in ne sme biti interpretirana kot specifikacija jamstev in kakovosti. Informacija se nanaša

samo na označeni specifični material in morda ne bo veljavna za tak material, če bo uporabljen v

kombinaciji s kakšnim drugim materialom ali postopkom, razen če to ni posebej navedeno v

tekstu.

PRILOGA: SCENARIJI IZPOSTAVLJENOSTI

Snovi po DPD+:

:

Naslednje snovi so glavne sestavine, ki prispevajo k scenariju izpostavljenosti za zmesi, skladno z

metodologijo DPD+:

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

P3-risil ECO

113703E

14 / 14

Pot

Snov

Št. CAS

Št. EINECS

Zaužitje

natrijev hidroksid

1310-73-2

215-185-5

Vdihavanje

natrijev hidroksid

1310-73-2

215-185-5

Kožno

natrijev hidroksid

1310-73-2

215-185-5

Oči

natrijev hidroksid

1310-73-2

215-185-5

vodno okolje

Ni snovi v sledeh

Fizikalne lastnosti snovi po DPD+:

Snov

Parni tlak

Topnost v vodi

Pow

Molska masa

natrijev hidroksid

1 g/ml

40 g/mol

Za preračun, ali so vaši nadaljnji pogoji obratovanja in ukrepi za obvladovanje tveganja varni,

prosimo, izračunajte faktor tveganja na spodaj navedeni spletni strani:

www.ecetoc.org/tra

Kratek naslov scenarija

izpostavljenosti

Procesno čiščenje; Cleaning In place (CIP) postopek

Deskriptorji uporabe

Glavne skupine uporabnikov

Industrijske uporabe: uporabe snovi kot takih ali v pripravkih na

industrijskih lokacijah

Sektorji končne uporabe

SU3: Industrijske uporabe: uporabe snovi kot takih ali v pripravkih

na industrijskih lokacijah

Skupine postopkov

PROC1: Uporaba v zaprtih procesih, izpostavljenost ni verjetna

PROC8b: Prenos snovi ali pripravka (polnjenje/ praznjenje) iz/ v

posode/ velike vsebnike na namenskih napravah

Kategorije izdelka

PC35: Izdelki za pranje in čiščenje (vključno z izdelki na osnovi

topil)

Kategorije sproščanja v

okolje

ERC4: Industrijska uporaba procesnih pripomočkov, ki se vključijo

v izdelke, v procesih in izdelkih

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Published on: Wed, 14 Nov 2018 The technical report reflects the outcome of the discussions and agreements that were reached in the pesticides peer review meeting on residues and maximum residue levels regarding the principles and guidance for application of the proportionality concept in the risk assessment methodologies used at European level for the estimation of the maximum residue levels for pesticides. In addition, practical experiences on the use of the proportionality approach gained by EFSA hav...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA published draft guidance for industry #243 “Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing MRLs and Withdrawal Periods.”

FDA - U.S. Food and Drug Administration

6-11-2018

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Published on: Fri, 02 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the Australian Government Department of Agriculture and Water Resources submitted two requests to the competent national authority in Denmark to set import tolerances for the active substance haloxyfop‐P in linseed and rapeseed. The data submitted in support of the request were found to be sufficient to derive maximum residue level (MRL) proposals for linseed and rapeseed. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

10-10-2018

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

The health risks associated with exposure to artificial UV radiation from tanning booths have been well established for many years now. ANSES points out that recent data on the subject support previous assessments: there is a proven cancer risk associated with UV radiation from artificial tanning equipment. The Agency therefore recommends that the public authorities take the necessary steps to prevent people from being exposed to artificial UV radiation from tanning booths used for cosmetic purposes.

France - Agence Nationale du Médicament Vétérinaire

21-9-2018

Scientific guideline:  Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

Scientific guideline: Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

This document provides a standard approach to be used across the European Union in the analysis of residue depletion data for the purpose of establishing withdrawal periods for edible tissues. Emphasis has been put on a statistical approach. As the method of first choice, a linear regression technique is recommended. A computerised version of the method described is available: Updated application software: withdrawal time calculation for tissues. Read together with the explanatory note on updated applica...

Europe - EFSA - European Food Safety Authority EFSA Journal

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EFSA Panel on Plant Protection Products and their Residues reviewed the guidance on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessment. The inclusion of aged sorption is a higher tier in the groundwater leaching assessment. The Panel based its review on a test with three substances taken from a data set provided by the European Crop Protection Association. Particular points of attention were the quali...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 This report describes the framework of collection, management and transmission of food safety data in the Federal Republic of Germany. To adjust optimally the data governance processes to the requirements defined by the EFSA, measures had been agreed upon in order to improve the specified situation. Subsequent methodological system enhancements related to data quality are given as well as structural adjustments and the development and implementation of suppo...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

The EU's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted new recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones (bone metastases). Xofigo should only be used in symptomatic patients who have had two previous treatments for prostate cancer and who cannot be treated with other medicines.

Danish Medicines Agency

23-8-2018

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

6-8-2018

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment drugs to treat opioid use disorder.

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

20-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

FDA posted a new batch of 43 product-specific guidances related to the development of generic drug products that includes three revised product-specific guidances for ADF opioid products. These guidances recommend specific in vivo studies and in vitro study considerations for abuse deterrence evaluations.

FDA - U.S. Food and Drug Administration

19-7-2018

Assessment of the safety of feminine hygiene products

Assessment of the safety of feminine hygiene products

Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...

France - Agence Nationale du Médicament Vétérinaire

18-7-2018

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

In a context where prevention of ambient air pollution is a real public health issue, questions are regularly asked about the value of recommending that the population wear personal protective equipment. This led ANSES to assess the potential health benefits of wearing "anti-pollution" masks. Its expert appraisal revealed a lack of data demonstrating a health benefit. To reduce the health impacts associated with ambient air pollution, the Agency reiterates the importance of prioritising action at the sou...

France - Agence Nationale du Médicament Vétérinaire

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

4-7-2018

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Cases of skin allergies and irritation related to clothing or footwear are regularly reported to the health authorities. Today ANSES is publishing the results of the expert appraisal it conducted to identify the chemicals likely to be found in these articles and possibly responsible for these cases. Further to this expert appraisal, the Agency is issuing recommendations on how to better protect consumers from the risks of skin allergies and irritation caused by the presence of these substances.

France - Agence Nationale du Médicament Vétérinaire

28-6-2018

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

The European monitoring strategy for air quality relies heavily on quality standards for a number of pollutants. Advances in knowledge on the toxicity of substances and their emissions in the atmosphere have shown that certain pollutants that may have an impact on human health are not currently taken into account in regulatory monitoring. ANSES therefore received a formal request from the Ministries of Ecology and Health to propose a list of new priority pollutants for this air quality monitoring to supp...

France - Agence Nationale du Médicament Vétérinaire

8-5-2018

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

The FDA has received reports associated with the use of these devices in the treatment of unruptured brain aneurysms that suggest some events of peri-procedural stroke and/or death may have been related to procedural risks or patient selection related factors. These factors include patients who had serious co-morbidities resulting in a reduced life expectancy, or who were intolerant to required anticoagulation or anti-platelet therapy.

FDA - U.S. Food and Drug Administration

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

15-2-2018

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

The Danish Medicines Agency recommends doctors not to start any new patients on the medicine Esmya (ulipristal) because of a rare, but possible, risk of developing serious liver injury.

Danish Medicines Agency

14-11-2017

The European Commission has published three recommendations for the clinical trials regulation

The European Commission has published three recommendations for the clinical trials regulation

In cooperation with the clinical trials expert group, the European Commission is updating and issuing new recommendations as a result of the regulation on clinical trials on medicinal products for human use.

Danish Medicines Agency

21-3-2017

New recommendation for phasing out zinc oxide for young pigs

New recommendation for phasing out zinc oxide for young pigs

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has confirmed a previous decision to phase out zinc oxide. Consequently, the CVMP has once more recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

19-12-2016

Zinc oxide for young pigs to be phased out

Zinc oxide for young pigs to be phased out

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

20-7-2016

Marketing authorisation for medicine for cows suspended in the EU/EEA

Marketing authorisation for medicine for cows suspended in the EU/EEA

On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.

Danish Medicines Agency

17-10-2014

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

The EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) recommends strengthening the restrictions on the use of the antiepileptic valproate due to the risk of malformations and developmental problems in children exposed to valproate in the womb.

Danish Medicines Agency

3-10-2014

Consultation procedure about medicinal products and safety measure requirements not completed yet

Consultation procedure about medicinal products and safety measure requirements not completed yet

On 5 September 2014, the Danish Health and Medicines Authority submitted a draft list of the medicinal products comprised by the new safety measures rules (Directive 2001/83) for consultation. The consultation period expired on 17 September 2014, and on 3 October we were to inform the European Commission of the medicinal products we recommend including in the common EU lists. We have received 22 consultation responses. But on 24 September 2014 the European Commission amended the original guideline for...

Danish Medicines Agency

25-2-2014

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

The European Medicines Agency (EMA) recommends to restrict the use of the osteoporosis medicine strontium ranelate (Protelos®) to patients with severe osteoporosis who cannot be treated with other medicines approved for osteoporosis.

Danish Medicines Agency

5-1-2012

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.

Danish Medicines Agency

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

1-12-2011

Danish Pharmacovigilance Update, 17 November 2011

Danish Pharmacovigilance Update, 17 November 2011

In this issue of Danish Pharmacovigilance Update, you can read about domperidone (Motilium® etc.) and potential risk of cardiac disorders, about the European Medicines Agency's recommendation on a lower dose of the antidepressant citalopram as well as about more interesting aspects of pharmacovigilance.

Danish Medicines Agency

4-11-2011

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.

Danish Medicines Agency

26-8-2011

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.

Danish Medicines Agency

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

27-5-2011

Consultation on the Reimbursement Committee's recommendation for glucosamine

Consultation on the Reimbursement Committee's recommendation for glucosamine

The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.

Danish Medicines Agency

6-5-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.

Danish Medicines Agency

21-10-2018

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting  ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting https://go.usa.gov/xPnyd .

FDA - U.S. Food and Drug Administration

9-10-2018

#ICYMI - FDA issues recommendations to help prevent surgical fires and      related patient injury. Click the link to read the recommendations:  https://go.usa.gov/xQdwG   #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

Click the link for a handy list of #FDA’s recommendations for using and  caring for your medical devices during a #hurricane.   https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

6-8-2018

Scientific guideline:  ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

Scientific guideline: ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide rec...

Europe - EMA - European Medicines Agency

18-7-2018

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity:  https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://healthsectorcouncil.org/health-sector-mobilizes-against-cyber-threats/ …

FDA - U.S. Food and Drug Administration

16-7-2018

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Active substance: Fluoxetine) - Centralised - Renewal - Commission Decision (2018)4770 of Mon, 16 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/133/R-18

Europe -DG Health and Food Safety

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

29-5-2018

FDA issues recommendations to help prevent surgical fires and related patient injury-  https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA - U.S. Food and Drug Administration